Access all of the content
Dr Jennifer Taylor-Cousar (National Jewish Health, Denver, CO, USA) explores what we have learnt so far about how COVID-19 is effecting patients with cystic fibrosis.
1. What is the risk to cystic fibrosis patients from COVID-19 and what have we learned from reported cases so far? (0:07)
2. It seems that, to date, cystic fibrosis patients have only experienced mild symptoms. What do think is the reason for this? (1:08)
3. How are healthcare providers managing the routine care of patients with cystic fibrosis during the pandemic? (2:58)
4. If a cystic fibrosis patient has COVID-19, how does this impact on their day to day treatment? (3:36)
5. How can cystic fibrosis patients with COVID-19 avoid infecting other people while using non-invasive ventilation in a hospital setting? (4:26)
Speaker disclosure: Dr Taylor-Cousar has acted as a PI on studies for Vertex and Proteostasis; a consultant/advisor for Proteostasis, Santhera, 4DMT and Vertex; and a speaker for Vertex. She has also received grant funding from the CF Foundation; serves on the CF Foundation’s Clinical Research Executive Committee and Clinical Research Advisory Board; and is chair-elect of the ATS Clinical Problems Assembly Programming Committee.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and supported by Touch Medical Media
Filmed on Thursday 9 April 2020.
Share this Video
Related Videos In Cystic Fibrosis
Molla Imaduddin Ahmed, ERS 2021: Tezacaftor/Ivacaftor Effect on Exercise Capacity in Adolescents with Cystic Fibrosis
It was a pleasure to speak with Dr Molla Imaduddin Ahmed (Leicester Childrens’ Hospital, Leicester, UK) around his abstract on ‘The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF.‘, which was presented at ERS International Congress 2021, 5-8 September 2021. Questions How useful is exercise capacity as a clinical endpoint for cystic […]
Molla Imaduddin Ahmed, ERS 2021: Advances in the Treatment of Cystic Fibrosis
It was great to talk with Dr Molla Imaduddin Ahmed (Leicester Childrens’ Hospital, Leicester, UK) around the impact of CFTR modulator therapies and exciting advances in the treatment of cystic fibrosis. Questions What has been the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies on the treatment of cystic fibrosis (CF)? (0:20) What […]
Jordana E Hoppe: Lumacaftor–ivacaftor in Young Children with Cystic Fibrosis
TouchRESPIRATORY got the opportunity to catch up with Dr Jordana E Hoppe (Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, US) to discuss the phase 3 extension study of lumacaftor–ivacaftor therapy in young children with cystic fibrosis homozygous for the F508del-CFTR mutation. Questions What are the unmet needs in the treatment of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!